🇺🇸 FDA
Pipeline program

Tarperprumig Placebo, Tarperprumig

ALXN1820-ANCA-201

Phase 2 small_molecule active

Quick answer

Tarperprumig Placebo, Tarperprumig for Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a Phase 2 program (small_molecule) at Alexion Europe SAS with 1 ClinicalTrials.gov record(s).

Program details

Company
Alexion Europe SAS
Indication
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials